ThromboGenics NV and BioInvent International AB will share an up-front payment of €50 million (US$77.5 million), plus up to €450 million more in milestones, by partnering their jointly developed first-in-class antiangiogenesis monoclonal antibody TB-403 with F. Hoffman-La Roche Ltd. (BioWorld Today)

Swiss vaccine developer AmVac AG is teaming up with Bayer AG subsidiary Icon Genetics GmbH to develop a plant-based production system for making an adjuvanted influenza vaccine. (BioWorld International)